Introduction
As the first line of defense in treating heart disease, cardiac medications can treat symptoms and slow disease advancement. If medicinal therapies do not limit disease advancement and provide symptomatic relief, percutaneous coronary interventions or coronary artery bypass graft surgery may be used to attempt to reopen the obstructed vessels. Although these interventions do not address the underlying disease, they do provide a palliative benefit and, in some subpopulations, may improve survival [1] . A group of patients are present, however, who have angina pectoris not controlled by medical treatment and who have diffuse obstructive coronary artery disease not amenable to conventional revascularization [2] . The prognosis for these patients without conventional options is poor [3] . Transmyocardial revascularization (TMR) is a surgical option that, when applied as sole therapy in selected patients within this difficult patient population, is acknowledged by the Society of Thoracic Surgeons Workforce on Evidence-Based Surgery [4] and the American Heart Association/ American College of Cardiology [5] as useful and effective. Among multiple prospective randomized trials with 1-year follow-up, TMR has provided superior angina relief, decreased rehospitalizations, and improved eventfree survival compared with continued medical management, with equivocal perfusion results [6] [7] [8] [9] [10] . year follow-up has demonstrated sustained and significantly superior angina relief following TMR compared with medical therapy [11] [12] [13] , with a survival benefit in one trial involving sicker class IV patients [11] . Nonetheless, the surgical thoracotomy that is required for open TMR carries with it a certain morbidity and mortality. In a procedure in which the primary clinical outcome is improved cardiac pain control (i.e. angina reduction), it is incumbent upon the treating physician to explore available options to optimize the patient experience postprocedurally. As such, to avoid the risks attendant with thoracotomy, several different catheterbased approaches have been developed to deliver percutaneous myocardial laser (PML) therapy. Using a uniquely designed, coaxial catheter system that is most similar to the surgically delivered, fiberoptic-based system [14] , several independent clinical trials have demonstrated significant symptomatic improvement over 1 year [15] [16] [17] , including a sham-controlled, double-blind trial that we conducted [17] . To evaluate the durability of this therapy, we collected data on 77 patients who underwent PML at our institution an average of 3 years ago and report on their angina class and clinical status postprocedurally.
Methods

Study design
From 1998 to 2003, consecutive patients (n = 77) were enrolled in controlled trials of PML therapy at a single institution (Haukeland Hospital, University of Bergen, Bergen, Norway). Approval from the local ethics committee and patient consent were obtained before enrollment. Included in this follow-up are all patients who were enrolled in the treated arm (n = 28) of the double blind, randomized, sham-controlled trial of PML therapy for which we previously reported 1-year outcomes [17] , and patients (n = 49) enrolled in a single-arm longitudinal study of PML therapy alone. The original selection criteria were the same among all patients: Canadian Cardiovascular Society (CCS) class III or IV chronic, stable angina pectoris despite optimally tolerated doses of two or more antianginal medications, ejection fraction Z 25%, wall thickness Z 8 mm in the target regions, objective evidence of reversible myocardial ischemia not amenable to conventional revascularization (assessed using exercise tolerance testing and follow-up stress myocardial perfusion scanning), typical anginal pain during the exercise tolerance test, and absence of exclusionary conditions (ST-elevation myocardial infarction within the prior 3 months, non-ST elevation infarction within prior 6 weeks, symptomatic heart failure with exercise test limited by dyspnea, significant ventricular dysrhythmias requiring chronic use of antiarrhythmic therapy, left ventricular thrombus, significant aortic valve stenosis, or unstable angina). Patients had their baseline angina class and ineligibility for conventional revascularization confirmed by an expert committee consisting of board-certified cardiologists and cardiothoracic surgeons. Details of randomized trial enrollment, baseline assessment, procedural details, and 1-year results were previously reported [17] . As required by the original ethics committee approval, patients who were randomized to sham procedure were offered PML therapy following the 1-year follow-up, constituting 21 of the 49 patients in the single arm study. As such, a randomized follow-up was not possible. This current follow-up includes angina class assessment performed by independent cardiologists using a standardized questionnaire, left ventricular ejection fraction by transthoracic echocardio-graphy, cardiovascular medication usage, mortality, and adverse events.
Percutaneous myocardial laser procedure
The interventional technique for PML therapy (Cardiogenesis Corporation, Foothill Ranch, California, USA) in our institution has been previously described [14, 17] . With the patient maintained under conscious sedation, nontransmural endocardial channels > 1 mm in diameter were created with four pulses of the holmium laser, delivered 75-150 ms after the QRS complex of the electrocardiogram. Approximately one channel was created per square centimeter of the endocardial surface targeted for treatment. Immediately after the procedure and through 24 h, serial evaluations by echocardiography and electrocardiography were conducted to rule out the occurrence of pericardial effusion, serious conduction abnormalities, myocardial infarction, and to assess wall motion.
Statistical analysis
Results are presented as mean ± SD for continuous data and as n (%) for categorical data. The standard Student's t-test and paired t-test were used for analysis of normally distributed continuous data. The Wilcoxon signed-rank test was used for the analysis of non-normally distributed data. Logistic regression was used to evaluate predictors of survival and angina improvement. P < 0.05 is considered to indicate statistical significance (SPSS software, Version 13; SPSS Inc., Chicago, Illinois, USA).
Results
Study population
Patient demographics are shown in Table 1 . As noted, these patients were primarily men (87%) at a mean age of 66 years, and had a significant history of cardiac risk factors, prior myocardial infarctions (70%), prior conventional revascularizations (90%), and triple vessel disease (85%). Baseline CCS class was distributed among class III (73%) and class IV (27%). All patients underwent PML as sole interventional therapy for angina pectoris at Haukeland University Hospital an average of 3.1 ± 0.9 years earlier (range: 1.7-5.7 years). To assess accurately the durability of angina relief among these patients, only those who survived and did not undergo additional revascularization procedures (1 year: n = 74; mean 3 years: n = 50) were included in the analysis for angina class. All surviving patients are included in the analyses for ejection fraction. All patients are accounted for in the analyses for mortality and adverse events.
Percutaneous myocardial laser results
Procedurally, 16 ± 5 PML channels (maximum: 25 channels) were placed per patient over procedure and laser times of 64 ± 21 and 34 ± 13 min, respectively. The primary target region was the lateral wall in 62 patients (81%); the inferior wall in 53 patients (69%); and the anterior wall in 25 patients (32%). The majority of patients (71%) were treated in two or more regions. Periprocedurally (within 24 h) there were no deaths, myocardial infarction, or cerebral embolism (stroke or transient ischemic attack). Myocardial perforation occurred in two patients (2.6%) requiring pericardiocentesis with no long-term sequelae. Minor observations included nonsustained ventricular tachycardia requiring no intervention in four patients (5%). Patients were discharged at a mean of 1.06 ± 0.3 days postprocedurally.
Mortality and morbidity
The procedural mortality for patients undergoing PML therapy in our institution was 0%. A total of 16 patients (21%) died during follow-up. Timing of these events post-PML (number of patients) was as follows: < 1 year (two); > 1 and < 2 years (four); > 2 and < 3 years (five); > 3 and < 4 years (three); > 4 years (two). 3%) ]. Baseline demographics were included in a multivariate logistic regression analysis of potential predictors of survival at the current follow-up. No baseline covariates were significant in this analysis. The only univariate predictor of survival at late follow-up was angina improvement at 1 year (odds ratio = 3.5; 95% confidence interval: 1-12; P = 0.04). Non-ST elevation myocardial infarction occurred in six patients, half of whom had a history of myocardial infarction. Timing of these events post-PML (number of patients) was as follows: < 1 year (one); > 1 and < 2 years (one); > 2 and < 3 years (two); > 3 years (two). None of these patients died during the follow-up period; however, all were nonresponders in terms of angina class improvement. Symptomatic heart failure necessitating use of diuretics occurred in two patients, of whom one had a history of congestive heart failure. Both events occurred > 4 years after PML, and both patients were nonresponders. One of these patients later died 5 years after PML from a cerebral stroke. A total of 11 patients underwent additional coronary revascularization because of the development of restenosis (five) or new disease (six): one patient underwent bypass grafting and 10 patients underwent percutaneous coronary intervention. Permanent atrial fibrillation developed in one patient at 3.8 years post-PML. A total of five patients were hospitalized and discharged during the follow-up period for nonspecific chest pain. Cardiac event-free survival, defined in the original protocols as freedom from cardiac death, myocardial infarction, stroke, transient ischemic attack, myocardial perforation, and rehospitalization, was 88% at 1 year and 66% at late follow-up.
Canadian Cardiovascular Society angina class
PML therapy using this device provided significant and sustained angina relief in no-option patients through a mean of 3.1 years (Fig. 1) . A significant reduction in mean CCS angina class from baseline (3.2 ± 0.4) was observed in 74 surviving patients, none of whom underwent an additional revascularization at 1 year (2.2 ± 1.1, P < 0.001), with 59% of the patients having no angina or being in CCS class I or II. This significant improvement was sustained at a mean of 3 years in the 50 surviving patients who did not undergo an additional revascularization, with 35 patients (70%) having no angina or being in class I or II. Improvement by one or more class was seen in 36 patients (72%), and by two or more classes in 22 patients (44%). The mean class at the current follow-up is 1.9 ± 1.2, which is significantly improved from baseline (P < 0.001) but is unchanged from the 1-year follow-up (P = 0.3). Thirty-nine patients (64%) had no angina or were in class I or II at 3 years, regardless of whether they required repeat revascularization. Baseline demographics were included in a multivariate logistic regression analysis of potential predictors of two or more class improvement in CCS angina class at the current follow-up. No baseline covariates were significant in this analysis. The only univariate predictors of such improvement at late follow-up were one or more class improvement at 1 year (odds ratio = 11; 95% confidence interval: 2-55; P = 0.003) and two or more class improvement at 1 year (odds ratio = 20; 95% confidence interval: 5-84; P < 0.001).
Left ventricular ejection fraction
Left ventricular ejection fraction was evaluated in all patients at baseline using transthoracic echocardiography. This result (0.58 ± 0.10) was found to be well preserved and not significantly changed in surviving patients at 1 year (0.57 ± 0.08) and at the current follow-up (0.57 ± 0.07).
Cardiac medications
At baseline, all patients were maintained on maximally tolerated doses of two or more antianginal medications consisting of b-blockers, calcium channel blockers, and nitrates. At 1 year, there were no significant dose changes from baseline. At an average of 3 years, significant reductions from baseline in the proportion of patients taking calcium channel blockers (65 vs. 59%, P = 0.02) and long-acting nitrates (94 vs. 82%, P = 0.03) were observed (Table 2) . Moreover, usage of nitrates and bblockers was significantly lower (P r 0.05) in patients who improved in angina class at the current follow-up than in patients who did not improve. No significant changes in the usage of other cardiac medications were observed.
Discussion
In three prospective, randomized interventional trials involving 'no option' class III/IV patients, including one trial that was sham-controlled, angina relief at 1 year was significantly better following PML using this laser-based delivery system than with continued medical management alone [15] [16] [17] . Among these trials, mortality following PML treatment was 0% procedurally, and ranged from 0 to 0.9% at 30 days, comparing very favorably with the 30-day mortality rates following the surgical approach (3.5%) [18] , which is similar to that following standard bypass surgery (3.1%) [19] . Survival at 1 year was statistically similar between randomized groups, ranging from 93 to 100% in PML patients, and 95 to 97% in medically managed patients. In light of these consistent and positive results at 1 year, it is appropriate to evaluate results in the longer term.
The present study is the first long-term follow-up of prospectively enrolled patients reported with PML therapy. Our results demonstrate that the substantial angina improvement seen at 1 year following PML, which was not attributable to patient bias (the placebo effect) or to investigator assessment bias, persists to a maximum of 5 years, and furthermore that survival is predicted by angina improvement. These results are consistent with the long-term follow-up results reported by Allen and colleagues [11] for the surgical holmium laser TMR system, wherein long-term survival was also predicted by angina improvement at 1 year and at follow-up. Moreover, the long-term clinical improvement we observed following PML is very similar to that reported by Aaberge and associates [12] following surgical TMR, in demographically comparable patients also in the Norwegian health system. The proportions of patients who experienced one or more class and two or more class angina improvement were 72 and 44%, respectively, in our follow-up (mean 3.1 years), compared with 61 and 24%, respectively, in the surgical follow-up (mean 3.6 years). The persistent improvement in angina observed by Aaberge is supported by a long-term follow-up of a series of 78 patients who received carbon dioxide TMR [13] . Although 5-year survival following carbon dioxide TMR was only 49%, surviving patients enjoyed an improved quality of life and a significant reduction in angina from baseline. Of course, it is only appropriate to compare the general results and trends, and not the specific magnitude of results, among the respective studies because of differences in patient populations, devices and procedures, numbers and locations of channels, and other aspects of study designs. Furthermore, PML channels originate endocardially and are nontransmural, whereas TMR channels originate epicardially and are transmural. These differences may potentially affect the contribution of myocardial denervation and angiogenic response to the observed symptomatic benefit, obviating further direct comparisons.
An important finding in our study relates to a potential concern that the mechanism explaining sustained clinical benefit of laser therapy may be denervation, thereby inducing silent ischemia and adverse sequelae without a substantial improvement in left ventricular function. In our series, the large majority of patients who died or suffered a myocardial infarction during follow-up were nonresponders and continued to have class III or IV angina before the event. Conversely, angina improvement at follow-up was found to be a significant independent predictor of survival, refuting silent ischemia as a possible risk. This is consistent with the blinded exercise core laboratory analysis of the larger randomized trial results at 1 year using this same device system [20] . In that report, Myers and associates report a similar 5% incidence of silent ischemia in PML and medically managed patients, and conclude that the device induces significant functional improvement and pain relief without substantial denervation or silent ischemia. A recent mechanistic evaluation of the commercial surgical laser systems by Duke University found that denervation does occur in the immediate postprocedural period; however, reinnervation occurs within 6 months [21] . Taken together with our 1year findings from the sham-controlled trial, these cumulative results would appear to indicate that mechanisms other than denervation or placebo effect are responsible for the significant benefits observed late and for long-term survival following laser therapy. Furthermore, it is striking in our study and in the surgical TMR long-term study that significant clinical improvement has been found to be predictive of long-term survival. Clearly, further research to enhance this effect, including the use of angiogenic cells and factors, is needed.
Lack of a control group is a limitation factor in this study limiting the validity of the results. We previously, however, excluded the placebo effect after PML [17] . Another limitation of this study is that it reflects the results from a single center, and was not designed to specifically elucidate the mechanism of persistent benefit. Nonetheless, as research continues in the treatment of advanced coronary artery disease, these data further support the aggressive use of PML therapy in 'no option' patients with medically refractory angina.
